Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures... Show more
STXS saw its Momentum Indicator move above the 0 level on August 12, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for STXS just turned positive on August 11, 2025. Looking at past instances where STXS's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
STXS moved above its 50-day moving average on August 08, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 178 cases where STXS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for STXS moved out of overbought territory on August 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 52 cases where STXS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
STXS broke above its upper Bollinger Band on August 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. STXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: STXS's P/B Ratio (178.571) is very high in comparison to the industry average of (10.917). P/E Ratio (0.000) is within average values for comparable stocks, (58.712). STXS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.855). STXS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (7.862) is also within normal values, averaging (38.490).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
a designer of robotic cardiology instrument navigation systems
Industry PharmaceuticalsOther
A.I.dvisor indicates that over the last year, STXS has been loosely correlated with TWST. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then TWST could also see price increases.
Ticker / NAME | Correlation To STXS | 1D Price Change % | ||
---|---|---|---|---|
STXS | 100% | +3.24% | ||
TWST - STXS | 36% Loosely correlated | -1.91% | ||
CERS - STXS | 35% Loosely correlated | -1.50% | ||
SMTI - STXS | 35% Loosely correlated | +0.86% | ||
RGEN - STXS | 33% Loosely correlated | -1.34% | ||
VCYT - STXS | 33% Poorly correlated | -1.58% | ||
More |
Ticker / NAME | Correlation To STXS | 1D Price Change % |
---|---|---|
STXS | 100% | +3.24% |
Pharmaceuticals category (391 stocks) | 32% Poorly correlated | +0.12% |
Pharmaceuticals: Other category (105 stocks) | 29% Poorly correlated | -0.29% |